Britain’s competition regulator has fined more than 10 drug firms a record combined 260 million pounds ($360 million) for overcharging the National Health Service (NHS) for a steroid which rose from 70p to 88 pounds a pack in under eight years.
The Competition and Markets Authority (CMA) said on Thursday that the breaches meant the NHS paid over 10,000% more for single packs of 10 mg and 20 mg hydrocortisone tablets in 2016 than they were paying in 2008.
Hydrocortisone is used to treat conditions where adrenal glands do not make sufficient hormones, including the life-threatening Addison’s disease.
The CMA said companies including Actavis, and its former parent and now Abbvie-owned Allergan, broke competition rules.
The companies engaged in practices including buying potential rivals to keep their versions off the market, increasing the price of hydrocortisone as sole providers, and continued to pay off the competition over the years, the CMA said.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI